Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €15.29 EUR
Change Today -0.06 / -0.39%
Volume 7.9K
As of 6:06 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

ab science sa (AB) Snapshot

Open
€15.40
Previous Close
€15.35
Day High
€15.40
Day Low
€15.22
52 Week High
02/10/15 - €18.93
52 Week Low
10/16/14 - €7.16
Market Cap
518.0M
Average Volume 10 Days
69.1K
EPS TTM
€-0.49
Shares Outstanding
33.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AB SCIENCE SA (AB)

Related News

No related news articles were found.

ab science sa (AB) Related Businessweek News

No Related Businessweek News Found

ab science sa (AB) Details

AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. The company markets Masitinib for the treatment of oncology and inflammatory diseases for dogs and cats. It markets its Masitinib under the Masivet brand name in Europe; and Kinavet brand name in the United States. The company is also developing Masitinib in human indications that are in various Phase II and Phase III clinical trials for the treatment of oncology, inflammatory, hematology, and central nervous system diseases, as well as for the treatment of indolent systemic mastocytosis, non controlled severe asthma, refractory rheumatoid arthritis, progressive forms of multiple sclerosis, amyothrophic lateral sclerosis, and Alzheimer's diseases. It serves hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

121 Employees
Last Reported Date: 04/30/15
Founded in 2001

ab science sa (AB) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €227.7K
Compensation as of Fiscal Year 2014.

ab science sa (AB) Key Developments

AB Science S.A. - Special Call

To discuss the current positioning of masitinib in MS; to discuss the scientific rationale for developing masitinib in MS; to discuss the efficacy and safety update on the on-going phase 3 study; and to discuss the market potential for masitinib in MS

AB Science S.A. Announces Successful Non Futility Test for Masitinib in Progressive Forms of Multiple Sclerosis

AB Science SA announced the successful completion of a futility analysis related to the masitinib phase 3 trial for the treatment of patients with primary progressive or relapse-free secondary progressive multiple sclerosis. Based on these results, the Independent Data Safety Monitoring Committee (IDMC) has recommended the continuation of the study. Phase 3 status: the ongoing phase 3 trial is a double-blind, randomized, placebo-controlled study (AB07002) designed to assess the safety and efficacy of masitinib in patients with primary progressive or relapse-free secondary progressive multiple sclerosis. The treatment period is 96 weeks. The main measures to assess efficacy of masitinib in this disease are: change in MSFC (Multiple Sclerosis Functional Composite), which is a three-part assessment instrument to measure leg function/ambulation, arm/hand function, and cognitive function. Change in the MSQOL-54 (Multiple Sclerosis Quality of Life 54 items), which is a quality of life measure. Change in EDSS (Expanded Disability Status Scale), which is a scale used for quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. The study is intended to enroll 600 patients. This study was assessed as non-futile by the IDMC. The characteristics of the futility test were as follows: performed after approximately one third of the planned study population had reached the 48 week treatment duration period Hypothesis that all the remaining patients to be enrolled in the study will follow the trend observed on the patient already enrolled at the time of futility analysis. P-value below 5%; conditional power (predictive probability of success) of 20% More importantly, the IDMC highlighted that the study was not futile on the three main assessment criteria, MSFC, MSQOL-54, and EDSS. A futility analysis tests the inability of a clinical study to achieve its efficacy objective. Therefore, a conclusion that a study is not futile suggests that a clinical study has the potential to achieve its stated efficacy objective. The study previously successfully passed all safety data reviews by the IDMC, indicating that there is no major or unexpected safety concern with masitinib in this patient population. The next step for this study is a second futility analysis once one third of patients have reached the 96 week time point. Then an interim analysis is expected once 50% of patients planned to be enrolled have reached the 96 week treatment duration period.

AB Science Sa Announces Successful Futility Test for Masitinib in c-Kit Mutated Metastatic Melanoma

AB Science SA announced the successful non futility analysis related to the masitinib phase 3 trial in metastatic melanoma, carrying a mutation in the juxta membrane domain of c-Kit. Based on these results, the Independent Data Safety Monitoring Committee (IDMC) has recommended continuation of the study. The ongoing phase 3 trial (AB08026) is an open-label, controlled study comparing masitinib to dacarbazine and designed to assess the safety and efficacy of masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta-membrane (JM) domain of c-Kit. The study's primary measure of efficacy is objective response rate. Secondary efficacy measures include progression-free survival and overall survival. The statistical hypothesis is based on detecting a response rate of about 40% with masitinib and 15% with dacarbazine. The study plans to enroll 120 patients. This study was assessed as non-futile by the IDMC. The characteristics of the futility test were as follows: performed after more than one-third of the planned study population had reached the time-point to assess efficacy, hypothesis that all remaining patients to be enrolled in the study will follow the trend observed in patients already enrolled at the time of futility analysis, P-value below 5% and Conditional power (predictive probability of success) of 20%. A futility analysis tests the inability of a clinical study to achieve its efficacy objective. Therefore, a conclusion that a study is not futile suggests that a clinical study has the potential to achieve its stated efficacy objective. The next step for this study is an interim analysis, expected once two-thirds of the planned study population had reached the time-point to assess efficacy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB:FP €15.29 EUR -0.06

AB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AB.
View Industry Companies
 

Industry Analysis

AB

Industry Average

Valuation AB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 217.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 203.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AB SCIENCE SA, please visit www.ab-science.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.